Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract

Latest news

10 Nov, 2021
Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections
08 Mar, 2021
Pneumagen Announces Neumifilâ„¢ is Efficacious In an Established Model of COVID-19 Infection
21 Jan, 2021
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

Meet the team